Tables

0.2.1	User charges "cheat sheet"	*page* 6
0.2.2	Payment mechanisms "cheat sheet"	16
1.1.1	Private OOP spending is the largest source of funding for health among LICs and LMICS	39
1.1.2	Share of government expenditure for health, education, military and debt interest payments, 2019	50
1.3.1	VHI plays a supplementary role in most countries	95
2.2.1	Value-based formulary tiers, incremental cost–effectiveness ratio thresholds and co-payment levels	178
2.2.2	Current 69 priority health problems in the AUGE benefits package	181
2.3.1	Evidence on demand- and supply-side disinvesting interventions	203
2.3.2	Surgical procedures under the remit of phase one of the NHS England EBI programme	212
2.5.1	Higher-income countries tend to favour a mix of public, non-profit and for-profit provision of LTC	255
2.5.2	Overview of the use of means-testing in public support for LTC	264
3.1.1	The impact of different primary care payment models on health care system objectives	289
3.2.1	Key types of hospital payment method	329
3.3.1	List of cross-sectional surveys on informal payments	373
3.3.2	Countries in the EU by highest/lowest prevalence of informal payments, 2021	386
3.3.3	Countries in Asia by highest/lowest prevalence of informal payments, 2020	388
3.5.1	Payment methods to support coordinated and integrated care	461
3.6.1	Risk adjusters used in needs-based formulae for allocating pooled funds, 2018	493

Published online by Cambridge University Press

3.6.2 Types of payment for nursing/care homes used in different countries 496
3.7.1 Key policy recommendations for donors and countries 534
3.8.1 International guiding instruments to frame public health threats and events and establish preparedness capacities 544
3.9.1 A selection of push and pull mechanisms available or proposed for incentivizing antibiotic R&D 580
3.9.2 Summary of initiatives incentivizing R&D 583
3.9.3 WHO priority pathogens list 592
3.10.1 Neglected diseases affect more than 1 billion people globally 612
3.10.2 Advantages and disadvantages of incentive mechanisms for innovation and access to innovation 628
3.10.3 PDPs have increased overall investment in R&D and innovation for neglected diseases 631
3.10.4 Selected examples of grants intermediaries 639
3.10.5 Fiscal incentives' effectiveness in stimulating neglected disease research is unclear 642
3.10.6 PRVs' impact on R&D is unclear because of a lack of data 648
3.10.7 Selected example of advanced market commitments 650
3.10.8 Selected examples of prizes 654

Published online by Cambridge University Press